摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(3-azido-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)daunorubicinone | 874384-80-2

中文名称
——
中文别名
——
英文名称
7-(3-azido-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)daunorubicinone
英文别名
3'-azido-3'-deamino daunorubicin;3'-azido-3'-deaminodaunorubicin;3'-azidodeaminodaunorubicin;3'-azidodaunorubicin;ADNR;3'-azido-deamino-daunorubicin;(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-azido-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
7-(3-azido-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)daunorubicinone化学式
CAS
874384-80-2
化学式
C27H27N3O10
mdl
——
分子量
553.525
InChiKey
RQILHTMNLJXCQG-VGBVRHCVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    40
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    174
  • 氢给体数:
    4
  • 氢受体数:
    12

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-(3-azido-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)daunorubicinone 在 palladium diacetate 4-二甲氨基吡啶 、 1,1'-bis(diphenylphosphino)ferrocene 、 甲酸:三乙胺 1:1N,N-二异丙基乙胺三苯基膦 、 potassium iodide 、 magnesium chloride 作用下, 以 四氢呋喃吡啶N,N-二甲基甲酰胺 为溶剂, 反应 10.5h, 生成 盐酸依达比星
    参考文献:
    名称:
    METHOD OF PRODUCING 4-DEMETHOXYDAUNORUBICIN
    摘要:
    本发明涉及一种合成4-去甲氧基多柔红霉素(伊达霉素)的方法,其化学结构如式(I),该方法涉及在软性Lewis酸存在下对3'-Prot-多柔红霉素进行去甲基化。本发明的方法不包括在碳C7处断裂糖苷键,因此导致合成周期更快,最终产物的产率提高。
    公开号:
    US20120277415A1
  • 作为产物:
    参考文献:
    名称:
    METHOD OF ARALKYLATION OF 4'-HYDROXYL GROUP OF ANTHRACYLINS
    摘要:
    本发明提供了一种利用芳基烷基化试剂R3-CH2X(例如BnBr)根据图1所示的反应途径进行蒽环素的芳基烷基化的方法。本发明认识到4-R1,3'-N3-多柔比星是适合选择性4'-O-苄基化的底物,产生4-R1,3'-N3-4'-O-芳基烷基-多柔比星(特别是4'-O-Bn-多柔比星)。因此,本发明提供了一种简单生产蒽环素4'-O-芳基烷基化衍生物的途径,可有效用于生产蒽环素。
    公开号:
    US20090176974A1
点击查看最新优质反应信息

文献信息

  • Spectroscopic, Viscositic and Molecular Modeling Studies on the Interaction of 3′-Azido-Daunorubicin Thiosemicarbazone with DNA
    作者:Fengling Cui、Qingfeng Liu、Hongxia Luo、Guisheng Zhang
    DOI:10.1007/s10895-013-1285-8
    日期:2014.1
    A new daunorubicin has been synthesized and structurally characterized. The interaction of native calf thymus DNA (ctDNA) with 3′-azido-daunorubicin thiosemicarbazone (ADNRT) was investigated under simulated physiological conditions by multi-spectroscopic techniques, viscometric measurements and molecular modeling study. It concluded that ADNRT could intercalate into the base pairs of ctDNA, and the fluorescence quenching by ctDNA was static quenching type. Thermodynamic parameters calculated suggested that the binding of ADNRT to ctDNA was mainly driven by hydrophobic interactions. The relative viscosity of ctDNA increased with the addition of ADNRT, which confirmed the intercalation mode. Furthermore, molecular modeling studies corroborate the above experimental results.
    我们合成了一种新的daunorubicin,并确定了其结构特征。在模拟生理条件下,通过多光谱技术、粘度测量和分子建模研究了原生小牛胸腺 DNA(ctDNA)与 3′-叠氮-daunorubicin thiosemicarbazone(ADNRT)的相互作用。结果表明,ADNRT 能插入到 ctDNA 的碱基对中,ctDNA 对其产生的荧光淬灭为静态淬灭。计算得出的热力学参数表明,ADNRT与ctDNA的结合主要由疏水相互作用驱动。ctDNA的相对粘度随着ADNRT的加入而增加,这证实了插层模式。此外,分子建模研究也证实了上述实验结果。
  • Syntheses and Biological Activities of 3‘-Azido Disaccharide Analogues of Daunorubicin against Drug-Resistant Leukemia
    作者:Guisheng Zhang、Lanyan Fang、Lizhi Zhu、Yanqiang Zhong、Peng George Wang、Duxin Sun
    DOI:10.1021/jm050916m
    日期:2006.3.1
    Anthracyclines, such as daunorubicin (DNR) and doxorubicin (Dox), are widely used for cancer therapy but are limited by drug resistance and cardiotoxicity. To overcome drug resistance, we synthesized a novel class of disaccharide analogues of DNR against drug-resistant leukemia. In these disaccharide analogues (1-6) the first (inner) sugar in the carbohydrate chain is a 3-azido-2,3,6-trideoxy-L-lyxo-alpha-hexopyranose; the second (outer) sugars that are linked via alpha(1 -> 4) to the first sugar are a series of uncommon sugars. Their cytotoxicities were examined in drug-sensitive leukemia cells K562 and doxorubicin-resistant K562/Dox cells by MTS assay. In drug-sensitive cells, compounds 1-6 were found to be active against leukemia K562 cells with IC50 in the nanomolar range (200-1100 nM), while compounds 2-5 with 2,6-dideoxy sugars showed better activity than compounds 1 and 6 with 2,3,6-trideoxy sugars. In doxorubicin-resistant K562/Dox cells, compounds 1, 3, and 5 exhibited much better activities (with IC50 between 0.29 and 2.0 mu M) than DNR (with IC50 > 5 mu M). Compound 3 emerged as the most active compound, showing at least 17-fold higher activity against drug-resistant cells than parent compound DNR. The IC50 values of compound 3 in both drug-sensitive and drug-resistant cells are identical, which indicates that compound 3 completely overcomes drug resistance. Structure-activity relationship (SAR) studies showed that the substitution and orientation of the 3-OH group in the second sugar significantly influence its activity against drug-resistant leukemia. These results suggest that sugar modifications of anthracyclines change their activity and overcome drug resistance.
  • WO2006/124720
    申请人:——
    公开号:——
    公开(公告)日:——
  • Syntheses and biological activity of bisdaunorubicins
    作者:Guisheng Zhang、Lanyan Fang、Lizhi Zhu、Duxin Sun、Peng George Wang
    DOI:10.1016/j.bmc.2005.08.014
    日期:2006.1
    To study the length and flexibility of the linkers between two monomers of bisdaunorubicins for their activity against cancer cells, seven bisdaunorubicins were rationally designed and synthesized through click chemistry. Their cytotoxicity was tested in leukemia cells with MTS assay. The results showed that the compounds with short linkers exhibited higher activity than the compounds with long linkers, while the flexibility of the linker also contributed to their activity. These results indicated that the length and flexibility of the linkers between two monomers in bisdaunorubicins are very critical to maintain their activity against cancer cells. (c) 2005 Elsevier Ltd. All rights reserved.
  • Method of producing 4-demethoxydaunorubicin
    申请人:Synbias Pharma AG
    公开号:EP2518077B1
    公开(公告)日:2016-01-06
查看更多

同类化合物

麻西罗霉素 领地霉素A盐酸盐 阿霉素醇 阿霉素醇 阿霉素醇 阿霉素 阿霉素 阿雷西霉素 阿洛二霉素A 阿克那霉素B 阿克那霉素 S 阿克拉霉素 铁(3+)氯化12,17-二乙烯基-3-(3-{[3-(1H-咪唑-1-基)丙基]氨基}-3-羰基丙基)-7-(3-甲氧基-3-羰基丙基)-2,8,13,18-四甲基卟吩-21,22-二负离子(1:1:1) 道诺霉素 贝鲁比星 诺拉霉素 表阿霉素 表柔比星杂质 表柔比星EP杂质F 苯甲胺,3-[4-(1,1-二甲基乙基)苯氧基]- 美多比星 罗多比星 紫红霉素A 磷酸,2-乙基己基酯,加合2,2'-亚氨基二[乙醇] 硫霉菌素E 硫霉菌素B 硫霉菌素 盐酸阿柔比星 盐酸表柔比星 盐酸莎巴比星 盐酸多柔比星 盐酸加柔比星 盐酸依达比星 盐酸佐柔比星 甲基N-[6-[(3-乙酰基-3,5,12-三羟基-10-甲氧基-6,11-二氧代-2,4-二氢-1H-并四苯-1-基)氧基]-3-羟基-2-甲基四氢吡喃-4-基]氨基甲酸酯 甲基7-乙酰氧基-4-({4-O-[3-O-乙酰基-2,6-二脱氧-4-O-(6-甲基-5-氧代四氢-2H-吡喃-2-基)己糖吡喃糖苷]-2,3,6-三脱氧-3-(二甲基氨基)己糖吡喃糖苷}氧基)-2-乙基-2,5,9-三羟基-6,11-二氧代-1,2,3,4,6,11-六氢-1-四c烯羧酸酯 甲基7,9-二乙酰氧基-4-({4-O-[3-O-乙酰基-2,6-二脱氧-4-O-(6-甲基-5-氧代四氢-2H-吡喃-2-基)己糖吡喃糖苷]-2,3,6-三脱氧-3-(二甲基氨基)己糖吡喃糖苷}氧基)-2-乙基-2,5-二羟基-6,11-二氧代-1,2,3,4,6,11-六氢-1-四c烯羧酸酯 甲基4-[5-[5-(4,5-二羟基-6-甲基四氢吡喃-2-基)氧基-4-羟基-6-甲基四氢吡喃-2-基]氧基-4-二甲基氨基-6-甲基四氢吡喃-2-基]氧基-2-乙基-2,5,7,10-四羟基-6,11-二氧代-3,4-二氢-1H-并四苯-1-羧酸酯 甲基4-({4-O-[3-O-乙酰基-2,6-二脱氧-4-O-(6-甲基-5-氧代四氢-2H-吡喃-2-基)己糖吡喃糖苷]-2,3,6-三脱氧-3-(二甲基氨基)己糖吡喃糖苷}氧基)-2-乙基-2,5,7,9-四羟基-6,11-二氧代-1,2,3,4,6,11-六氢-1-四c烯羧酸酯 甲基4-({4-(二甲基氨基)-5-[(2,9-二甲基-3-氧代八氢-2H,5aH-二吡喃并[2,3-b:4',3'-e][1,4]二恶英-7-基)氧基]-6-甲基四氢-2H-吡喃-2-基}氧基)-2-乙基-2,5,7,9-四羟基-6,11-二氧代-1,2,3,4,6,11-六氢-1-并四苯羧酸酯 甲基2-乙基-2,5-二羟基-6,11-二氧代-4-({2,3,6-三脱氧-4-O-[2,6-二脱氧-4-O-(6-甲基-5-氧代四氢-2H-吡喃-2-基)己糖吡喃糖苷]-3-(二甲基氨基)己糖吡喃糖苷}氧基)-1,2,3,4,6,11-六氢-1-T乙基r乙酰基烯羧酸酯 甲基(1R,2S,4S)-2,5,7-三羟基-6,11-二羰基-2-(2-羰基丙基)-4-({2,3,6-三脱氧-3-(二甲氨基)-4-O-[(2S,5S,6S)-5-{[(2S,5S,6S)-5-羟基-6-甲基四氢-2H-吡喃-2-基]氧代}-6-甲基四氢-2H-吡喃-2-基]-α-L-来苏-六吡喃糖基}氧代)-1,2,3,4,6,1 甲基(1R,2R,4S)-4-[4-二甲基氨基-5-[4-羟基-6-甲基-5-(6-甲基-5-氧代四氢吡喃-2-基)氧基四氢吡喃-2-基]氧基-6-甲基四氢吡喃-2-基]氧基-2-乙基-2,5,7,10-四羟基-6,11-二氧代-3,4-二氢-1H-并四苯-1-羧酸酯 环丁羧酸,3-(氯羰基)-2,2-二甲基-,甲基酯 烬灰红菌素X 烬灰红菌素B盐酸盐 流柔比星 洋红霉素13-环己亚基腙 氯化N-[9-(2-羧基-4-氰硫基<硫代氰酸基>苯基)-6-(二甲氨基)-3H-占吨-3-亚基]-N-甲基甲铵 氢氧化N,N,N-三甲基丁烷-1-铵